FDA Clearance Tracker · P110019-S115
XIENCE Alpine Everolimus Eluting Coronary Stent Systems (XIENCE Alpine EECSS), XIENCE Sierra Everolimus Eluting Coronary
Last checked: Nov 20, 2026Latest source record: Jun 25, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Jun 25, 2021
Approved
Time to decision
179 days
Received Dec 28, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P110019-S115
- Device name
- XIENCE Alpine Everolimus Eluting Coronary Stent Systems (XIENCE Alpine EECSS), XIENCE Sierra Everolimus Eluting Coronary
- Applicant
- Abbott Vascular
- Applicant location
- Santa Clara, CA
- Received
- Dec 28, 2020
- Decided
- Jun 25, 2021
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P110019
Device type
- Device type
- Coronary drug-eluting stent (NIQ)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the XIENCE Alpine Everolimus Eluting Coronary Stent Systems (XIENCE Alpine EECSS), XIENCE Sierra Everolimus Eluting Coronary Stent Systems (XIENCE Sierra EECSS), and the XIENCE Skypoint Everolimus Eluting Coronary Stent System (XIENCE Skypoint EECSS).The XIENCE [Alpine / Sierra / Skypoint] stent system is indicated for improving coronary artery luminal diameter in patients, including those at high risk for bleeding and those with diabetes mellitus, with symptomatic heart disease due to de novo native coronary artery lesions (length <= 32 mm) with reference vessel diameters of >= 2.25 mm to <= 4.25 mm. In addition, the XIENCE [Alpine / Sierra / Skypoint] stent system is indicated for treating de novo chronic total coronary occlusions.
Source documents
Other decisions for Abbott Vascular
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- XACT Carotid Stent SystemPMA supplement
P040038-S043 · Decided Feb 7, 2024 · 225 days after receipt · Panel Track
Device type: Stent, carotid (NIM) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.